Oskar Ström

Publications
CV
Public outreach and news

Articles

Article: OSTEOPOROSIS INTERNATIONAL. 2021;32(7):1301-1311
A novel economic framework to assess the cost-effectiveness of bone-forming agents in the prevention of fractures in patients with osteoporosis
Soreskog E; Borgstrom F; Lindberg I; Strom O; Willems D; Libanati C; Kanis JA; Stollenwerk B; Charokopou M
Article: OSTEOPOROSIS INTERNATIONAL. 2021;32(3):585-594
Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden
Soreskog E; Lindberg I; Kanis JA; Akesson KE; Willems D; Lorentzon M; Strom O; Berling P; Borgstrom F
Article: OSTEOPOROSIS INTERNATIONAL. 2020;31(8):1525-1533
Real-world effectiveness of osteoporosis treatment in the oldest old
Strom O; Lauppe R; Ljunggren O; Sphangeus A; Ortsater G; O'Kelly J; Akesson K
Article: BONE. 2020;134:115286
Risk of major osteoporotic fracture after first, second and third fracture in Swedish women aged 50 years and older
Soreskog E; Strom O; Spangeus A; Akesson KE; Borgstrom F; Banefelt J; Toth E; Libanati C; Charokopou M
Article: ARCHIVES OF OSTEOPOROSIS. 2019;14(1):45
Differing impact of clinical factors on the risk of fracture in younger and older women in the general population and an osteoporosis clinic population
Lauppe R; Akesson KE; Ljunggren O; Spangeus A; Ortsater G; Feudjo-Tepie M; Strom O
Article: OSTEOPOROSIS INTERNATIONAL. 2019;30(3):601-609
Risk of imminent fracture following a previous fracture in a Swedish database study
Banefelt J; Akesson KE; Spangeus A; Ljunggren O; Karlsson L; Strom O; Ortsater G; Libanati C; Toth E
Article: QUALITY OF LIFE RESEARCH. 2018;27(3):707-716
Quality of life after hip, vertebral, and distal forearm fragility fractures measured using the EQ-5D-3L, EQ-VAS, and time-trade-off: results from the ICUROS
Svedbom A; Borgstrom F; Hernlund E; Strom O; Alekna V; Bianchi ML; Clark P; Curiel MD; Dimai HP; Jurisson M; Uuskula A; Lember M; Kallikorm R; Lesnyak O; McCloskey E; Ershova O; Sanders KM; Silverman S; Tamulaitiene M; Thomas T; Tosteson ANA; Jonsson B; Kanis JA
Article: OSTEOPOROSIS INTERNATIONAL. 2018;29(3):557-566
Quality of life for up to 18 months after low-energy hip, vertebral, and distal forearm fractures-results from the ICUROS
Svedbom A; Borgstom F; Hernlund E; Strom O; Alekna V; Bianchi ML; Clark P; Curiel MD; Dimai HP; Jurisson M; Kallikorm R; Lember M; Lesnyak O; McCloskey E; Sanders KM; Silverman S; Solodovnikov A; Tamulaitiene M; Thomas T; Toroptsova N; Uuskula A; Tosteson ANA; Jonsson B; Kanis JA
Article: ARCHIVES OF OSTEOPOROSIS. 2017;12(1):81
Exploring methods for comparing the real-world effectiveness of treatments for osteoporosis: adjusted direct comparisons versus using patients as their own control.
Karlsson L; Mesterton J; Tepie MF; Intorcia M; Overbeek J; Ström O
Article: OSTEOPOROSIS INTERNATIONAL. 2015;26(10):2401-2411
Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis
Karlsson L; Lundkvist J; Psachoulia E; Intorcia M; Strom O
Article: OSTEOPOROSIS INTERNATIONAL. 2015;26(1):315-325
Residual effect after oral bisphosphonate treatment and healthy adherer effects-the Swedish adherence register analysis (SARA)
Strom O; Landfeldt E; Garellick G
Article: ARCHIVES OF OSTEOPOROSIS. 2015;10(1):222
Swedish osteoporosis care
Jonsson E; Eriksson D; Akesson K; Ljunggren O; Salomonsson S; Borgstrom F; Strom O
Article: OSTEOPOROSIS INTERNATIONAL. 2013;24(7):1991-1999
The impact of different health dimensions on overall quality of life related to kyphoplasty and non-surgical management
Borgstrom F; Olafsson G; Strom O; Tillman JB; Wardlaw D; Boonen S; Miltenburger C
Article: OSTEOPOROSIS INTERNATIONAL. 2013;24(4):1491-1502
Intervention thresholds for denosumab in the UK using a FRAX^A®-based cost-effectiveness analysis
Strom O; Jonsson B; Kanis JA
Article: OSTEOPOROSIS INTERNATIONAL. 2013;24(3):811-823
The International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS)-quality of life during the first 4 months after fracture
Borgstrom F; Lekander I; Ivergard M; Strom O; Svedbom A; Alekna V; Bianchi ML; Clark P; Curiel MD; Dimai HP; Jurisson M; Kallikorm R; Lesnyak O; McCloskey E; Nassonov E; Sanders KM; Silverman S; Tamulaitiene M; Thomas T; Tosteson ANA; Jonsson B; Kanis JA
Article: OSTEOPOROSIS INTERNATIONAL. 2013;24(1):355-367
Balloon kyphoplasty compared to vertebroplasty and nonsurgical management in patients hospitalised with acute osteoporotic vertebral compression fracture: a UK cost-effectiveness analysis
Svedbom A; Alvares L; Cooper C; Marsh D; Strom O
Article: BONE. 2012;51(4):637-642
The comparative gastrointestinal tolerability of proprietary versus generic alendronate in patients treated for primary osteoporosis
Landfeldt E; Strom O
Article: JOURNAL OF ARTHROPLASTY. 2012;27(7):1261-1266
Costs Related to Hip Disease in Patients Eligible for Total Hip Arthroplasty
Rolfson O; Strom O; Karrholm J; Malchau H; Garellick G
Article: OSTEOPOROSIS INTERNATIONAL. 2012;23(8):2201-2209
The association between automatic generic substitution and treatment persistence with oral bisphosphonates
Stroem O; Landfeldt E
Article: HUMAN REPRODUCTION. 2012;27(3):760-769
Patient preferences for characteristics differentiating ovarian stimulation treatments
Landfeldt E; Jablonowska B; Norlander E; Persdotter-Eberg K; Thurin-Kjellberg A; Wramsby M; Strom O
Article: OSTEOPOROSIS INTERNATIONAL. 2012;23(2):433-443
Adherence to treatment of primary osteoporosis and its association to fractures-the Swedish Adherence Register Analysis (SARA)
Landfeldt E; Strom O; Robbins S; Borgstrom F
Article: CALCIFIED TISSUE INTERNATIONAL. 2011;89(3):234-245
Gastrointestinal Tolerability and Patterns of Switching in Patients Treated for Primary Osteoporosis: The Swedish Adherence Register Analysis (SARA)
Landfeldt E; Lang A; Robbins S; Strom O
Article: OSTEOPOROSIS INTERNATIONAL. 2011;22(3):967-982
Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis
Jonsson B; Strom O; Eisman JA; Papaioannou A; Siris ES; Tosteson A; Kanis JA
Article: OSTEOPOROSIS INTERNATIONAL. 2011;22(3):955-965
Cost-effectiveness of bazedoxifene incorporating the FRAXA® algorithm in a European perspective
Borgstrom F; Strom O; Kleman M; McCloskey E; Johansson H; Oden A; Kanis JA
Article: BONE. 2011;48(2):380-388
The societal burden of poor persistence to treatment of osteoporosis in Sweden
Landfeldt E; Lundkvist J; Strom O
Article: ARCHIVES OF OSTEOPOROSIS. 2011;6:59-155
Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA).
Ström O; Borgström F; Kanis JA; Compston J; Cooper C; McCloskey EV; Jönsson B
Article: BONE. 2010;47(5):966-974
Identifying cost-effective treatment with raloxifene in postmenopausal women using risk algorithms for fractures and invasive breast cancer
Ivergard M; Strom O; Borgstrom F; Burge RT; Tosteson ANA; Kanis J
Article: OSTEOPOROSIS INTERNATIONAL. 2010;21(9):1599-1608
Cost-effectiveness of balloon kyphoplasty in patients with symptomatic vertebral compression fractures in a UK setting
Strom O; Leonard C; Marsh D; Cooper C
Article: BONE. 2010;47(2):430-437
FRAX® and its applications in health economics-Cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an example
Strom O; Borgstrom F; Kleman M; McCloskey E; Oden A; Johansson H; Kanis JA
Article: OSTEOPOROSIS INTERNATIONAL. 2010;21(3):495-505
The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAXA®
Borgstrom F; Strom O; Coelho J; Johansson H; Oden A; McCloskey EV; Kanis JA
Article: OSTEOPOROSIS INTERNATIONAL. 2010;21(2):339-349
The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis
Borgstrom F; Strom O; Coelho J; Johansson H; Oden A; McCloskey E; Kanis JA
Article: JOURNAL OF MEDICAL ECONOMICS. 2010;13(3):381-392
Cost effectiveness of teriparatide and PTH(1-84) in the treatment of postmenopausal osteoporosis.
Borgström F; Ström O; Marin F; Kutahov A; Ljunggren O
Article: JOURNAL OF WOMEN'S HEALTH. 2009;18(10):1669-1677
Cost-Effectiveness of Hormone Therapy in the United States
Lekander I; Borgstrom F; Strom O; Zethraeus N; Kanis JA
Article: MENOPAUSE INTERNATIONAL. 2009;15(1):19-25
Cost-effectiveness of hormone replacement therapy for menopausal symptoms in the UK.
Lekander I; Borgström F; Ström O; Zethraeus N; Kanis JA
Article: OSTEOPOROSIS INTERNATIONAL. 2009;20(1):23-34
Incorporating adherence into health economic modelling of osteoporosis
Strom O; Borgstrom F; Kanis JA; Jonsson B
Article: OSTEOPOROSIS INTERNATIONAL. 2008;19(6):819-827
The cost-effectiveness of the treatment of high risk women with osteoporosis, hypertension and hyperlipidaemia in Sweden
Zethraeus N; Strom O; Borgstrom F; Kanis JA; Jonsson B
Article: ACTA ORTHOPAEDICA. 2008;79(2):269-280
Long-term cost and effect on quality of life of osteoporosis-related fractures in Sweden
Strom O; Borgstrom F; Zethraeus N; Johnell O; Lidgren L; Ponzer S; Svensson O; Abdon P; Ornstein E; Ceder L; Thorngren KG; Sernbo I; Jonsson B
Article: BONE. 2008;42(2):294-306
Cost effectiveness of hormone therapy in women at high risks of fracture in Sweden, the US and the UK -: Results based on the Women's Health Initiative randomised controlled trial
Lekander I; Borgstrom F; Strom O; Zethraeus N; Kanis JA
Article: OSTEOPOROSIS INTERNATIONAL. 2007;18(8):1047-1061
Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries -: an economic evaluation based on the fracture intervention trial
Strom O; Borgstrom F; Sen SS; Boonen S; Haentjens P; Johnell O; Kanis JA
Article: BONE. 2007;40(6):1602-1609
The societal burden of osteoporosis in Sweden
Borgstrom F; Sobocki P; Strom O; Jonsson B
Article: EUROPEAN PSYCHIATRY. 2007;22(3):146-152
The economic burden of depression in Sweden from 1997 to 2005
Sobocki P; Lekander I; Borgstrom F; Strom O; Runeson B
Article: OSTEOPOROSIS INTERNATIONAL. 2006;17(12):1781-1793
An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting -: Based on the results of the SOTI and TROPOS trials
Borgstrom F; Jonsson B; Strom O; Kanis JA
Show more

All other publications

Thesis / dissertation: 2020
Pharmacoepidemiology and health economics of adherence to pharmaceutical fracture prevention
Ström, Oskar
Editorial comment: EUROPEAN RESPIRATORY JOURNAL. 2020;55(4):1902476
NORDSTAR: paving the way for a new era in asthma research
Geale K; Darabi H; Lindh M; Wahl HF; Strom O; Cao H; Alvares L; Dodge R; Loefroth E; Altraja A; Backer V; Backman H; Bjermer L; Bossios A; Aarli BB; Dahlen B; Hilberg O; Janson C; Kankaanranta H; Karjalainen J; Kauppi P; Kilpelainen M; Lehmann S; Lehtimaki L; Lundback B; Sandstrom T; Ulrik CS; Sverrild A; Viinanen A; von Bulow A; Yasinska V; Porsbjerg C
Letter: OSTEOPOROSIS INTERNATIONAL. 2012;23(7):2063-2065
Comment on: Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis.
Jönsson B; Ström O; Eisman JA; Papaioannou A; Siris ES; Tosteson A; Kanis JA
Review: LAKARTIDNINGEN. 2011;108(7):336-339
[FRAX--model for 10-year fracture risk assessment. Support in the treatment of osteoporosis, according to preliminary Swedish guidelines].
Johansson H; Kanis JA; Ljunggren O; Ström O; Svensson O; Mellström D
Review: OSTEOPOROSIS INTERNATIONAL. 2007;18(1):9-23
Cost-effectiveness of the treatment and prevention of osteoporosis -: a review of the literature and a reference model
Zethraeus N; Borgstrom F; Strom O; Kanis JA; Jonsson B

Employments

Affiliated to Research, Department of Medicine, Huddinge, Karolinska Institutet, 2024-2025

Degrees and Education

Degree Of Doctor Of Philosophy, Department of Learning, informatics, Management and Ethics, Karolinska Institutet, 2020

Articles

All other publications

Employments

Degrees and Education

News from KI

Events from KI